Norris Medicines Ratios

Norris Medicines Ltd Ratios

The Norris Medicines Ltd Ratios page provides a complete fundamental analysis of Norris Medicines Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Norris Medicines Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Norris Medicines Ltd (NSE: , BSE: 524414) is currently trading at ₹14.49, with a market capitalization of ₹0. As a major player in the Health technology sector and Pharmaceuticals: major industry, Norris Medicines Ltd remains a key stock for fundamental analysis using Norris Medicines Ltd Ratios.

Norris Medicines Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Norris Medicines Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Norris Medicines Ltd Ratios.

Historically, the Norris Medicines Ltd P/E ratio has shown strong fluctuations:

The decline in Norris Medicines Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Norris Medicines Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Norris Medicines Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Norris Medicines Ltd P/S ratio currently stands at 0, an important part of Norris Medicines Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Norris Medicines Ltd P/S ratio indicates cautious market sentiment.

Norris Medicines Ltd Price to Cash Flow Ratio (P/CF)

The Norris Medicines Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Norris Medicines Ltd Price to Cash Flow Ratio:

The declining Norris Medicines Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Norris Medicines Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Norris Medicines Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Norris Medicines Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Norris Medicines Ltd EV/EBITDA ratio is currently 0, a key metric in Norris Medicines Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Norris Medicines Ltd EV/EBITDA indicates balanced valuation.

Norris Medicines Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Norris Medicines Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Norris Medicines Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Norris Medicines Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Norris Medicines Ltd Ratios Analysis Summary

The Norris Medicines Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Norris Medicines Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Norris Medicines Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.